4-(morpholinomethyl)-N-phenylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(morpholinomethyl)-N-phenylbenzamide
• 英文别名: 4-[(morpholin-4-yl)methyl]-N-phenylbenzamide；4-(morpholin-4-ylmethyl)-N-phenylbenzamide
• 化学式: C₁₈H₂₀N₂O₂
• 分子量: 296.369
• InChiKey: CBCNPBXVHORZNA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  吗啉 、 4-氯甲基-N-苯基苯甲酰胺 以 四氢呋喃 、 水 为溶剂， 以141 mg的产率得到4-(morpholinomethyl)-N-phenylbenzamide
  参考文献：
  名称：

  Synthesis and structure–activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors

  摘要：

  Hypoxia-inducible factor-1 (HIF-1) is the chief transcription factor regulating hypoxia-driven gene expression. HIF-1 overexpression is associated with poor prognosis in several cancers and therefore represents an attractive target for novel antitumor agents. We explored small molecule inhibitors of the HIF-1 pathway. Using high-throughput-screening, we identified benzanilide compound 1 (IC50=560 nM) as a seed. Subsequent extensive derivatization led to the discovery of compounds 43a and 51d, with anti-HIF-1 activities in vitro (IC50=21 and 0.47 nM, respectively), and in vivo. Additionally, 43a (12.5-100mg/kg) also displayed in vivo anti-tumor efficacy, without influencing body weight.

  DOI：

  10.1016/j.bmc.2014.07.020

文献信息

• Small molecule anti-scarring agents
  申请人：UNIVERSITY OF ROCHESTER

  公开号：US10548911B2

  公开（公告）日：2020-02-04

  Disclosed are methods of treating fibrosis in a patient in need thereof that includes administering to the patient an amount of an active agent, as identified herein, that is therapeutically effective to inhibit myofibroblast formation and thereby treat the fibrosis. Also disclosed is a recombinant cell line that includes a recombinant gene that expresses a detectable expression product in a dose-dependent response to TGFβ, as well as methods of identifying a compound that inhibits TGFβ-mediated expression of the detectable expression product.

  公开了治疗有需要的患者纤维化的方法，包括向患者施用一定量的本文所确定的活性剂，该活性剂对抑制肌成纤维细胞的形成从而治疗纤维化具有治疗效果。还公开了一种重组细胞系，该细胞系包括以对TGFβ的剂量依赖性反应表达可检测表达产物的重组基因，以及鉴定抑制TGFβ介导的可检测表达产物表达的化合物的方法。
• Synthesis and structure–activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors
  作者：Satoshi Nagao、Yoshinobu Yamane、Setsuo Funasaka、Keigo Tanaka、Kazuki Miyazaki、Yoshihiko Kotake、Jun-ichi Kamata、Saori Watanabe-Miyano、Osamu Toyama、Yoichi Ozawa、Yoshiharu Mizui、Kiyoshi Okamoto、Daisuke Ito

  DOI：10.1016/j.bmc.2014.07.020

  日期：2014.10

  Hypoxia-inducible factor-1 (HIF-1) is the chief transcription factor regulating hypoxia-driven gene expression. HIF-1 overexpression is associated with poor prognosis in several cancers and therefore represents an attractive target for novel antitumor agents. We explored small molecule inhibitors of the HIF-1 pathway. Using high-throughput-screening, we identified benzanilide compound 1 (IC50=560 nM) as a seed. Subsequent extensive derivatization led to the discovery of compounds 43a and 51d, with anti-HIF-1 activities in vitro (IC50=21 and 0.47 nM, respectively), and in vivo. Additionally, 43a (12.5-100mg/kg) also displayed in vivo anti-tumor efficacy, without influencing body weight.